The Modulatory Effect of Lead Drug Candidates on Inflammatory Gene Expression in Sepsis: A Mini-Review

Author(s): Samuel Mawuli Adadey*, Michael Bright Yakass, Seth Agyemang, Samuel Duodu.

Journal Name: Current Drug Discovery Technologies

Volume 16 , Issue 1 , 2019

Submit Manuscript
Submit Proposal

Graphical Abstract:


Abstract:

Sepsis is a debilitating clinical syndrome of systemic inflammation in response to microorganisms especially Gram-positive and Gram-negative bacteria. A minority of sepsis cases could be due to non-pathogenic insult such as trauma. Much of the tissue and organ injury observed among septic patients is a consequence of the inflammatory response. The search for effective treatments of sepsis has led to several studies by different research groups across the globe. Although many targets and molecules have been identified, there is still no effective treatment for sepsis. The aim of this report is to review the literature on drugs and drug candidates against sepsis and how they modulate the expression of inflammatory genes. Many compounds have been identified to regulate inflammatory gene expression by interacting with targets such as topoisomerase 1 and nuclear factor kappa B, which regulate the production of pro- and anti-inflammatory cytokines. Even though these compounds appear promising as potential drugs against sepsis, no effective therapies have been discovered to date and thus the fight against sepsis continues.

Keywords: Sepsis, drug candidate, gene regulation, inflammation, NF-kappa B, macrophages.

[1]
Li W, Wang Y, Wang X, et al. Esculin attenuates endotoxin shock induced by lipopolysaccharide in mouse and NO production in vitro through inhibition of NF-kappaB activation. Eur J Pharmacol 2016; 791: 726-34.
[2]
Chaudhry H, Zhou J, Zhong Y, et al. Role of cytokines as a double-edged sword in sepsis. In Vivo 2013; 27: 669-84.
[3]
Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.
[4]
Wiersinga WJ, Leopold SJ, Cranendonk DR, van der Poll T. Host innate immune responses to sepsis. Virulence 2014; 5: 36-44.
[5]
Laurent-Rolle M, Morrison J, Rajsbaum R, et al. The interferon signaling antagonist function of yellow fever virus NS5 protein is activated by type I interferon. Cell Host Microbe 2014; 16: 314-27.
[6]
Stearns-Kurosawa DJ, Osuchowski MF, Valentine C, Kurosawa S, Remick DG. The pathogenesis of sepsis. Annu Rev Pathol 2011; 6: 19-48.
[7]
Seeley EJ, Matthay MA, Wolters PJ. Inflection points in sepsis biology: from local defense to systemic organ injury. Am J Physiol Lung Cell Mol Physiol 2012; 303: L355-63.
[8]
Ferrer R, Artigas A, Suarez D, et al. Effectiveness of treatments for severe sepsis: A prospective, multicenter, observational study. Am J Physiol Lung Cell Mol Physiol 2009; 180: 861-6.
[9]
Stone R. Search for sepsis drugs goes on despite failures. Science 1994; 264: 365-8.
[10]
Cohen J, Guyatt G, Bernard GR, et al. New strategies for clinical trials in patients with sepsis and septic shock. Crit Care Med 2001; 29: 880-6.
[11]
Opal SM, Dellinger RP, Vincent J-L, Masur H, Angus DC. The next generation of sepsis trials: What’s next after the demise of recombinant human activated Protein C? Crit Care Med 2014; 42: 1714-23.
[12]
Kellum JA, Kong L, Fink MP, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: Results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 2007; 167: 1655-63.
[13]
Calvano SE, Xiao W, Richards DR, et al. A network-based analysis of systemic inflammation in humans. Nature 2005; 437: 1032-7.
[14]
Maslove DM, Wong HR. Gene expression profiling in sepsis: Timing, tissue, and translational considerations. Trends Mol Med 2014; 20: 204-13.
[15]
Tang BM, McLean AS, Dawes IW, Huang SJ, Lin RC. The use of gene-expression profiling to identify candidate genes in human sepsis. Am J Respir Crit Care Med 2007; 176: 676-84.
[16]
Kouzine F, Levens D, Baranello L. DNA topology and transcrip-tion. Nucleus 2014; 5: 195-202.
[17]
Rialdi A, Campisi L, Zhao N, et al. Topoisomerase 1 inhibition suppresses inflammatory genes and protects from death by inflammation. Science 2016; 352: 1-35.
[18]
Hoesel B, Schmid JA. The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer 2013; 12: 1-15.
[19]
McKay LI, Cidlowski JA. Cross-talk between nuclear factor-κB and the steroid hormone receptors: Mechanisms of mutual antagonism. J Mol Endocrinol 1998; 12: 45-56.
[20]
Lawrence T. The nuclear factor NF-κB pathway in inflammation. Cold Spring Harb Perspect Biol 2009; 1: a001651-62.
[21]
Niu X, Yao H, Li W, et al. Delta-Amyrone inhibits lipopolysaccharide-induced inflammatory cytokines and protects against endotoxic shock in mice. Chem Biol Interact 2015; 240: 354-61.
[22]
Zhai J, Guo Y. Paeoniflorin attenuates cardiac dysfunction in endotoxemic mice via the inhibition of nuclear factor-kappaB. Biomed Pharmacother 2016; 80: 200-6.
[23]
Hung Y-L, Fang S-H, Wang S-C, et al. Corylin protects LPS-induced sepsis and attenuates LPS-induced inflammatory response. Sci Rep 2017; 7: 462-99.
[24]
Huang S-S, Deng J-S, Lin J-G, Lee C-Y, Huang G-J. Anti-inflammatory effects of trilinolein from Panax notoginseng through the suppression of NF-κB and MAPK expression and proinflammatory cytokine expression. Am J Chin Med 2014; 42: 1485-506.
[25]
Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001; 276: 11199-203.
[26]
Niu X, Mu Q, Li W, et al. Protective effects of esculentic acid against endotoxic shock in Kunming mice. Int Immunopharmacol 2014; 23: 229-35.
[27]
Wang N, Huang Y, Li A, et al. Hydrostatin-TL1, an Anti-Inflammatory Active Peptide from the Venom Gland of Hydrophis cyanocinctus in the South China Sea. Int J Mol Sci 2016; 17(11): E1940.
[28]
Zheng X, Wang N, Yang Y, Chen Y, Liu X, Zheng J. Insight into the inhibition mechanism of kukoamine B against CpG DNA via binding and molecular docking analysis. RSC Advances 2016; 6: 85756-62.
[29]
Liu X, Zheng X, Wang N, et al. a novel dual inhibitor of LPS and CpG DNA, is a potential candidate for sepsis treatment. Br J Pharmacol 2011; 162: 1274-90.
[30]
Lecker SH, Goldberg AL, Mitch WE. Protein degradation by the ubiquitin–proteasome pathway in normal and disease states. J Am Soc Nephrol 2006; 17: 1807-19.
[31]
Zhang R, Li R, Liu Y, Tang Y. 1449: Bortezomib Protects Endothelial Barrier Disruption In Acute Inflammation. Crit Care Med 2018; 46: 708-11.
[32]
Leng L, Bucala R. Insight into the biology of macrophage Migration Inhibitory Factor (MIF) revealed by the cloning of its cell surface receptor. Cell Res 2006; 16: 162-8.
[33]
Calandra T, Roger T. Macrophage migration inhibitory factor: A regulator of innate immunity. Nat Rev Immunol 2003; 3: 791-800.
[34]
Grieb G, Merk M, Bernhagen J, Bucala R. Macrophage Migration Inhibitory Factor (MIF): a promising biomarker. Drug News Perspect 2010; 23: 257-66.
[35]
Dabideen DR, Cheng KF, Aljabari B, Miller EJ, Pavlov VA, Al-Abed Y. Phenolic hydrazones are potent inhibitors of macrophage migration inhibitory factor proinflammatory activity and survival improving agents in sepsis. J Med Chem 2007; 50: 1993-7.
[36]
Cvetkovic I, Al-Abed Y, Miljkovic D, et al. Stosic-Grujicic, Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes. Endocrinology 2005; 146: 2942-51.
[37]
Opal SM, Cross AS. Clinical trials for severe sepsis. Past failures, and future hopes. Infect Dis Clin North Am 1999; 13: 285-97.
[38]
Greisman SE, Johnston CA. Failure of antisera to J5 and R595 rough mutants to reduce endotoxemic lethality. J Infect Dis 1988; 157: 54-64.
[39]
Vincent J-L, Sun Q, Dubois M-J. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 2002; 34: 1084-93.
[40]
Bone RC, Fisher CJ Jr, Clemmer TP, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317: 653-8.
[41]
Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis 1988; 138: 62-8.
[42]
Balk RA. Steroids for septic shock*: Back from the dead?(Pro). Chest 2003; 123: 490S-9S.
[43]
Venkatesh B, Finfer S, Cohen J, et al. Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med 2018.; [Epub ahead of print]
[44]
Toner P, McAuley DF, Shyamsundar M. Aspirin as a potential treatment in sepsis or acute respiratory distress syndrome. Crit Care 2015; 19: 374-84.
[45]
U.S.N.L.O. Medicine. Aspirin for Treatment of Severe Sepsis Clinicaltrialsgov
[46]
Laterre P-F. Clinical trials in severe sepsis with drotrecogin alfa (activated). Crit Care 2007; 11: 1-7.
[47]
Iskander KN, Osuchowski MF, Stearns-Kurosawa DJ, et al. Sepsis: Multiple abnormalities, heterogeneous responses, and evolving understanding. Physiol Rev 2013; 93: 1247-88.
[48]
Wang N, Huang Y, Li A, et al. Hydrostatin-TL1, an Anti-Inflammatory Active Peptide from the Venom Gland of Hydrophis cyanocinctus in the South China Sea. Int J Mol Sci 2016; 17: 1-15.
[49]
Šafránek R, Ishibashi N, Oka Y, Ozasa H, Shirouzu K, Holeček M. Modulation of inflammatory response in sepsis by proteasome inhibition. Int J Exp Pathol 2006; 87: 369-72.
[50]
Shih M, Chen L, Tsai P, Cherng J. In vitro and in vivo therapeutics of β-thujaplicin on LPS-induced inflammation in macrophages and septic shock in mice. Int J Immunopathol Pharmacol 2012; 25: 39-48.
[51]
Rim H-K, Cho W, Sung SH, Lee K-T. Nodakenin suppresses lipopolysaccharide-induced inflammatory responses in macrophage cells by inhibiting tumor necrosis factor receptor-associated factor 6 and nuclear factor-κB pathways and protects mice from lethal endotoxin shock. J Pharmacol Exp Ther 2012; 342: 654-64.
[52]
D’Acquisto F, May MJ, Ghosh S. Inhibition of nuclear factor kappa B (NF-B). Mol Interv 2002; 2: 22-33.
[53]
Chao W-W, Kuo Y-H, Lin B-F. Anti-inflammatory activity of new compounds from Andrographis paniculata by NF-κB transactivation inhibition. J Agric Food Chem 2010; 58: 2505-12.
[54]
O’Neil J, Ammit A, Clark A. MAPK p38 regulates inflammatory gene expression via tristetraprolin: Doing good by stealth. Int J Biochem Cell Biol 2018; 94: 6-9.
[55]
Mongardon N, Dyson A, Singer M. Pharmacological optimization of tissue perfusion. Br J Anaesth 2009; 103(1): 82-8.
[56]
Singer M, De Santis V, Vitale D, Jeffcoate W. Multiorgan failure is an adaptive, endocrine-mediated, metabolic response to overwhelming systemic inflammation. Lancet 2004; 364: 545-8.
[57]
Conway-Morris A, Wilson J, Shankar-Hari M. Immune Activation in Sepsis. Crit Care Clin 2018; 34: 29-42.
[58]
Abraham E. Nuclear Factor-κB and Its role in sepsis-associated organ failure. J Infect Dis 2003; 187: S364-9.
[59]
Aimbire F, Santos F, Albertini R, Castro-Faria-Neto H, Mittmann J, Pacheco-Soares C. Low-level laser therapy decreases levels of lung neutrophils anti-apoptotic factors by a NF-κB dependent mechanism. Int Immunopharmacol 2008; 8: 603-5.
[60]
Ross J, Elliott P. The proteasome: A new target for novel drug therapies. Am J Clin Pathol 2015; 1: 637-46.
[61]
Bleicher KH, Böhm H-J, Müller K, Alanine AI. A guide to drug discovery: Hit and lead generation: Beyond high-throughput screening. Nat Rev Drug Discov 2003; 2: 369.
[62]
Decque A, Joffre O, Magalhaes JG, et al. Sumoylation coordinates the repression of inflammatory and anti-viral gene-expression programs during innate sensing. Nat Immunol 2016; 17: 140-9.
[63]
Padhy B, Gupta Y. Drug repositioning: Re-investigating existing drugs for new therapeutic indications. J Postgrad Med 2011; 57: 153-64.
[64]
Lee CH. Resolvins as new fascinating drug candidates for inflammatory diseases. Arch Pharm Res 2012; 35: 3-7.
[65]
Spite M, Norling LV, Summers L, et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 2009; 461: 1287-91.
[66]
Chen F, Fan X, Wu Y, et al. Resolvin D1 improves survival in experimental sepsis through reducing bacterial load and preventing excessive activation of inflammatory response. Eur J Clin Microbiol Infect Dis 2014; 33: 457-64.
[67]
Mittur A. A Simultaneous Mixed-Effects Pharmacokinetic Model for Nefopam, N-desmethylnefopam, and Nefopam N-Oxide in Human Plasma and Urine. Eur J Drug Metab Pharmacokinet 2018; 43(4): 391-404.
[68]
Hobai IA, Edgecomb J, LaBarge K, Colucci WS. Dysregulation of intracellular calcium transporters in animal models of sepsis induced cardiomyopathy. Shock (Augusta, Ga) 2015; 43: 3-15.
[69]
Novak KR, Nardelli P, Cope TC, et al. Inactivation of sodium channels underlies reversible neuropathy during critical illness in rats. J Clin Invest 2009; 119: 1150-8.
[70]
Pasparakis M, Vandenabeele P. Necroptosis and its role in inflammation. Nature 2015; 517: 311-20.
[71]
N.C. Institue, Sorafenib Tosylate NIH. NIH Cancer Institute.
[72]
Martens S, Jeong M, Tonnus W, et al. Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury. Cell Death Dis 2017; 8: e2904.
[73]
Kwak S, Ku S-K, Kang H, Baek M-C, Bae J-S. Methylthiouracil, a new treatment option for sepsis. Vascul Pharmacol 2017; 88: 1-10.
[74]
Rudis MI, Basha MA, Zarowitz BJ. Is it time to reposition vasopressors and inotropes in sepsis? Crit Care Med 1996; 24: 525-37.
[75]
Jung B, Kim J, Bae J-S. Dabrafenib, as a novel insight into drug repositioning against secretory group IIa phospholipase A2. Int J Immunopathol Pharmacol 2016; 12: 415-21.


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 16
ISSUE: 1
Year: 2019
Page: [48 - 56]
Pages: 9
DOI: 10.2174/1570163815666180227162926

Article Metrics

PDF: 26
HTML: 3